Crinetics Pharmaceuticals, Inc.
CRNXDelisted Sep 1, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658247
Crinetics Pharmaceuticals, Inc. was delisted on Sep 1, 2026; its insiders filed their last Form 4 on Sep 1, 2026; 267 institutions reported holding it in 13F filings for Q2 2026, worth $4.63B in total; no superinvestor held it.
Q4 2024 vs. Q3 2024
How the institutions holding Crinetics Pharmaceuticals, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 235 | 3 | 247 | +15 |
| Shares | 84.5M | 167.4K | 99.7M | +15.3M (+18.2%) |
| Value | $4.32B | $8.55M | $5.10B | +$783.6M (+18.2%) |
3 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (37)
Institutions that held Crinetics Pharmaceuticals, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (22)
Institutions that held Crinetics Pharmaceuticals, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Dimensional Fund Advisors LP | 392,196 | $20.0M |
| Vestal Point Capital, LP | 205,000 | $10.5M |
| Maplelane Capital, LLC | 160,000 | $8.18M |
| Senator Investment Group LP | 135,000 | $6.90M |
| Baker Bros. Advisors LP | 103,927 | $5.31M |
| Man Group plc | 100,188 | $5.12M |
| Trexquant Investment LP | 62,679 | $3.20M |
| EAM Investors, LLC | 57,216 | $2.92M |
| Balyasny Asset Management LLC | 53,042 | $2.71M |
| Squarepoint Ops LLC | 34,646 | $1.77M |
| Advantage Alpha Capital Partners LP | 8,640 | $441.5K |
| Nebula Research & Development LLC | 6,727 | $343.8K |
| Valence8 US LP | 6,684 | $341.6K |
| Two Sigma Investments, LP | 5,414 | $276.7K |
| Acadian Asset Management LLC | 4,717 | $241.0K |
| Allspring Global Investments Holdings, LLC | 1,786 | $91.3K |
| Values First Advisors, Inc. | 1,644 | $84.0K |
| Raleigh Capital Management Inc. | 400 | $20.4K |
| Hillsdale Investment Management Inc. | 130 | $6.64K |
| Group One Trading, L.P. | 42 | $2.15K |
| CIBC Private Wealth Group, LLC | 15 | $767 |
| Capital Performance Advisors LLP | 8 | $409 |
Not filed for Q4 2024 yet (3)
Institutions that held Crinetics Pharmaceuticals, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Ghost Tree Capital, LLC | 150,000 | $7.67M |
| PEAK6 Investments LLC | 10,000 | $511.0K |
| Raymond James & Associates | 7,358 | $376.0K |